Third Rock Ventures

Investor type Venture Capital
Founders Kevin Starr Mark Levin Robert Tepper

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 124
Average round size
info
The average size of a deal this fund participated in
$49M
Portfolio companies 61
Rounds per year 8.27
Lead investments 30
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.51
Exits 32
Key employees 13
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Third Rock Ventures appeared to be the VC, which was created in 2007. The company was established in North America in United States. The main department of described VC is located in the Boston.

We can highlight the next thriving fund investment areas, such as Pharmaceutical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Foundation Medicine, Afferent Pharmaceuticals, Relay Therapeutics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

The higher amount of exits for fund were in 2015. The real fund results show that this VC is 28 percentage points more often commits exit comparing to other companies. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in 7-12 deals every year. This Third Rock Ventures works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2012. Despite it in 2019 the fund had an activity.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Third Rock Ventures, startups are often financed by Venrock, Flybridge Capital Partners, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Flagship Pioneering, ARCH Venture Partners, Polaris Partners. In the next rounds fund is usually obtained by Wellington Management, Fidelity Management and Research Company, Venrock.

The current fund was established by Kevin Starr, Mark Levin, Robert Tepper. We also calculated 13 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Third Rock Ventures:
Typical Co-investors
Third Rock Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Third Rock Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AdMaster China, Shanghai
Asia America MultiTechnology Association (AAMASV) California, Palo Alto, United States
Big Ban angels Spain, Valencia, Valencian Community
Blockhead Capital California, Santa Monica, United States
Chart Venture Partners New York, New York, United States
Crossventures Germany, Köln, Nordrhein-Westfalen
Daiwa Securities SMBC Principal Investments Japan, Tokyo
E-House Capital China, Shanghai
Hitachi Systems Japan, Tokyo
Innozate -
Intelsat Luxembourg, Luxembourg
Mieza Capital Connecticut, Darien, United States
North Sky Capital Minneapolis, Minnesota, United States
Palm Commerce Information Technology China, Guangdong, Tianjin
Rainbow Technologies California, Irvine, United States
Tongbei Zongheng Beijing, Beijing, China
Velocity Partners Bellevue, United States, Washington
Walking Ventures England, London, United Kingdom
WizarPOS China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

MOMA Therapeutics

Biotechnology
Therapeutics
$150M10 May 2022 Cambridge, Massachusetts, United States

Celsius Therapeutics

Biotechnology
Emergency Medicine
Genetics
Health Care
$83M24 Mar 2022 Cambridge, Massachusetts, United States

Septerna

Biotechnology
$100M27 Jan 2022 San Francisco, California, United States

Ambys Medicines

Biotechnology
Medical
Therapeutics
$47M21 Dec 2021 -

Cedilla Therapeutics

Biotechnology
Health Care
Therapeutics
$25M25 Oct 2021 Cambridge, Massachusetts, United States

Asher Bio

Biotechnology
Therapeutics
$108M01 Sep 2021 San Francisco, California, United States

Abata Therapeutics

Biotechnology
Medical
Therapeutics
$95M23 Jun 2021 Cambridge, Massachusetts, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$82M13 May 2021 Cambridge, Massachusetts, United States

Asher Bio

Biotechnology
Therapeutics
$55M23 Mar 2021 San Francisco, California, United States
News
Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Flare Therapeutics Raises $82M in Series A Financing

– Flare Therapeutics is a biotechnology company based in Cambridge, Mass.
– The company raised $82m in Series A financing.
– The round was led by Third Rock Ventures with participation from Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management.
– The new investment will be used for further advancement of the company’s lead program in precision oncology toward the clinic.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Third Rock Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: